ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO586

Antisense Oligonucleotide Knock Down of Uromodulin: A Potential Treatment Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD)

Session Information

Category: Genetic Diseases of the Kidneys

  • 1202 Genetic Diseases of the Kidneys: Non-Cystic

Authors

  • Morgan, Kathy Ye, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
  • Jungels, Nino, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
  • Jinadasa, Tushare, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
  • Greer, Christopher, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
  • Garcia, Stephanie, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
  • Tan, Xuyu, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
  • Adhikari, Kailash, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
  • Guerlavais, Vincent, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
  • Kim, Kevin, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
  • Oliver, Ryan A., Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
  • Malmberg, Annika, Sarepta Therapeutics Inc, Cambridge, Massachusetts, United States
Background

Autosomal Dominant Tubulointerstitial Kidney Disease-Uromodulin (ADTKD-UMOD) is a genetic disease caused by destabilizing mutations in the uromodulin (UMOD) or Tamm-Horsfall protein. Misfolded UMOD protein aggregates and accumulates inside the loop of Henle and the distal convoluted tubule, leading to progressive and irreversible chronic kidney disease. We hypothesized that peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) could knock down UMOD expression and potentially reduce the disease-causing UMOD aggregation inside the cells.

Methods

A library of PPMOs was designed to bind to the complementary sequences of the mouse Umod gene and induce nonsense-mediated decay. These PPMOs were screened in mIMCD-3 cells, which express endogenous transcript to identify the most active compounds. The most efficacious PPMO compound was tested in both wildtype and UMOD C93F mice, a well characterized disease model of ATDKD, to determine the ability of the PPMO to reduce UMOD expression at the transcript and protein levels.

Results

A single dose of lead PPMO resulted in a 70% knockdown of Umod transcript that led to protein reduction that was sustained for at least 28 days. Furthermore, UMOD protein expression was reduced in the UMOD C93F animals after a single dose of PPMO.

Conclusion

This study shows the ability of PPMO technology to reduce UMOD transcript and protein levels in vitro and in vivo.

Funding

  • Commercial Support – Sarepta